Article

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.

Upper Respiratory Medicine, Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, United Kingdom.
Journal of Allergy and Clinical Immunology (Impact Factor: 11.25). 10/2007; 120(3):688-95. DOI: 10.1016/j.jaci.2007.05.034
Source: PubMed

ABSTRACT The combination of anti-IgE (omalizumab) therapy with ragweed injection immunotherapy for seasonal allergic rhinitis results in a significant reduction in systemic side effects and enhanced efficacy compared with immunotherapy alone. One proposed mechanism of immunotherapy is to induce regulatory antibodies that inhibit facilitated antigen presentation.
We sought to determine whether the combination protocol has a cumulative effect on inhibition of facilitated antigen presentation both during and after discontinuation of treatment.
Ragweed allergen immunotherapy with and without omalizumab therapy was tested in a 4-arm, double-blind, placebo-controlled study. Flow cytometry was used to detect serum inhibitory activity for IgE-facilitated CD23-dependent allergen binding to B cells as a surrogate marker for facilitated antigen presentation. Serum ragweed-specific IgG4 was measured by means of ELISA.
Immunotherapy alone resulted in partial inhibition of allergen-IgE binding after 5 to 19 weeks of treatment compared with baseline (P < .01). Complete inhibition of allergen-specific IgE binding was observed in both treatment groups receiving omalizumab (P < .001). Allergen-specific IgG4 levels were only increased after immunotherapy (P < .05), both in the presence and absence of anti-IgE treatment. Combined treatment resulted in the induction of long-lasting inhibitory antibody function for up to 42 weeks compared with either treatment alone.
Ragweed immunotherapy induced serum regulatory antibodies that partially blocked binding of allergen-IgE complexes to B cells. Additional treatment with anti-IgE, by directly blocking IgE binding to CD23, completely inhibited allergen-IgE binding.
The combination of ragweed immunotherapy and anti-IgE resulted in prolonged inhibition of allergen-IgE binding compared with either treatment alone, events that might contribute to enhanced efficacy.

0 Bookmarks
 · 
88 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30% of the population. Although applied for 100 years to cure allergy, SIT still faces several problems related to side effects and limited efficacy. Currently, allergen-SIT is performed with vaccines based on allergen extracts that can cause severe, often life threatening, anaphylactic reactions as well as new IgE sensitization to other allergens present in the extract. Low patient adherence and high costs due to long duration (3 to 5 years) of treatment have been commonly reported. Several strategies have been developed to tackle these issues and it became possible to produce recombinant allergen-SIT vaccines with reduced allergenic activity.
    World Allergy Organization Journal 01/2014; 7(1):23.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The immunology database and analysis portal (ImmPort) system is the archival repository and dissemination vehicle for clinical and molecular datasets created by research consortia funded by the National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology, and Transplantation. With nearly 100 datasets now publicly available and hundreds of downloads per month, ImmPort is an important source for raw data and protocols from clinical trials, mechanistic studies, and novel methods for cellular and molecular measurements. To facilitate data transfer, templates for data representation and standard operating procedures have also been created and are also publicly available. ImmPort facilitates transparency and reproducibility in immunology research, serves as an important resource for education, and enables newly generated hypotheses and data-driven science.
    Immunologic Research 05/2014; · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our aim was to assess the eventual impact of pretreatment with omalizumab on the tolerance and efficacy of specific immunotherapy (SIT). Based on a collection of experiences, we report observations on 10 groups of patients who have received that therapeutic combination. Six of these observations involved patients sensitized to bees; their SIT was stopped because of problems with tolerance. In these six observations, different sorts of pretreatment with omalizumab was considered effective, which allowed bee venom SIT to be started and then maintained. While no randomized clinical trial has evaluated the effect of omalizumab treatment on tolerance to hymenoptera venoms, a number of published reports emphasize the efficacy of this pretreatment in improving tolerance to this SIT. Four observations concerned patients with severe allergic asthma due to sensitization to mites. In three of these observations, the association of omalizumab and mite SIT was considered effective in terms of control of the asthma and tolerance to the SIT; the combination was not considered effective in the fourth case. This collection of observations and an analysis of the literature have allowed us to emphasize the role of pretreatment with omalizumab in improving tolerance to SIT with hymenoptera venom. In the context of respiratory allergies, there are arguments for the combination of these two therapeutic modes in spite of the difficulty of applying it, especially in the case of severe asthma.
    Revue Française d'Allergologie 09/2014; · 0.35 Impact Factor

Full-text (3 Sources)

Download
30 Downloads
Available from
Jun 1, 2014